nodes	percent_of_prediction	percent_of_DWPC	metapath
Temsirolimus—CYP2D6—Hydroxyurea—head and neck cancer	0.146	0.238	CbGbCtD
Temsirolimus—CYP3A7—Docetaxel—head and neck cancer	0.0924	0.151	CbGbCtD
Temsirolimus—CYP3A7-CYP3A51P—Docetaxel—head and neck cancer	0.0924	0.151	CbGbCtD
Temsirolimus—CYP3A5—Docetaxel—head and neck cancer	0.0693	0.113	CbGbCtD
Temsirolimus—ABCB1—Vinblastine—head and neck cancer	0.0547	0.0896	CbGbCtD
Temsirolimus—CYP2D6—Vinblastine—head and neck cancer	0.0516	0.0844	CbGbCtD
Temsirolimus—ABCB1—Docetaxel—head and neck cancer	0.0451	0.0738	CbGbCtD
Temsirolimus—CYP3A4—Vinblastine—head and neck cancer	0.0328	0.0537	CbGbCtD
Temsirolimus—CYP3A4—Docetaxel—head and neck cancer	0.027	0.0442	CbGbCtD
Temsirolimus—Exfoliative rash—Docetaxel—head and neck cancer	0.00675	0.0309	CcSEcCtD
Temsirolimus—Septic shock—Fluorouracil—head and neck cancer	0.00537	0.0246	CcSEcCtD
Temsirolimus—Pulmonary fibrosis—Hydroxyurea—head and neck cancer	0.00512	0.0235	CcSEcCtD
Temsirolimus—Mucosal inflammation—Hydroxyurea—head and neck cancer	0.00407	0.0186	CcSEcCtD
Temsirolimus—Lacrimal structural disorder—Docetaxel—head and neck cancer	0.00398	0.0182	CcSEcCtD
Temsirolimus—Platelet count decreased—Hydroxyurea—head and neck cancer	0.00379	0.0174	CcSEcCtD
Temsirolimus—Febrile neutropenia—Hydroxyurea—head and neck cancer	0.00374	0.0172	CcSEcCtD
Temsirolimus—Pericardial effusion—Docetaxel—head and neck cancer	0.00285	0.0131	CcSEcCtD
Temsirolimus—Extravasation—Vinblastine—head and neck cancer	0.00283	0.013	CcSEcCtD
Temsirolimus—Rash generalised—Docetaxel—head and neck cancer	0.00275	0.0126	CcSEcCtD
Temsirolimus—Rectal haemorrhage—Vinblastine—head and neck cancer	0.00273	0.0125	CcSEcCtD
Temsirolimus—Cellulitis—Vinblastine—head and neck cancer	0.00272	0.0124	CcSEcCtD
Temsirolimus—Febrile neutropenia—Fluorouracil—head and neck cancer	0.0027	0.0123	CcSEcCtD
Temsirolimus—Pulmonary fibrosis—Docetaxel—head and neck cancer	0.00266	0.0122	CcSEcCtD
Temsirolimus—Lacrimal disorder—Docetaxel—head and neck cancer	0.00262	0.012	CcSEcCtD
Temsirolimus—Prurigo—Docetaxel—head and neck cancer	0.00253	0.0116	CcSEcCtD
Temsirolimus—Nail disorder—Fluorouracil—head and neck cancer	0.0025	0.0115	CcSEcCtD
Temsirolimus—Interstitial pneumonia—Docetaxel—head and neck cancer	0.00242	0.0111	CcSEcCtD
Temsirolimus—Creatinine increased—Hydroxyurea—head and neck cancer	0.00237	0.0108	CcSEcCtD
Temsirolimus—Lymphopenia—Docetaxel—head and neck cancer	0.00229	0.0105	CcSEcCtD
Temsirolimus—Mucosal inflammation—Docetaxel—head and neck cancer	0.00211	0.00968	CcSEcCtD
Temsirolimus—Rash maculo-papular—Hydroxyurea—head and neck cancer	0.00205	0.00938	CcSEcCtD
Temsirolimus—Febrile neutropenia—Docetaxel—head and neck cancer	0.00195	0.00891	CcSEcCtD
Temsirolimus—Deep vein thrombosis—Docetaxel—head and neck cancer	0.00192	0.00881	CcSEcCtD
Temsirolimus—Extravasation—Fluorouracil—head and neck cancer	0.00186	0.00851	CcSEcCtD
Temsirolimus—Nail disorder—Docetaxel—head and neck cancer	0.0018	0.00827	CcSEcCtD
Temsirolimus—Cellulitis—Fluorouracil—head and neck cancer	0.00178	0.00817	CcSEcCtD
Temsirolimus—Herpes simplex—Fluorouracil—head and neck cancer	0.00176	0.00806	CcSEcCtD
Temsirolimus—Dermatitis bullous—Hydroxyurea—head and neck cancer	0.00171	0.00784	CcSEcCtD
Temsirolimus—Haemoglobin decreased—Docetaxel—head and neck cancer	0.0017	0.00779	CcSEcCtD
Temsirolimus—Interstitial lung disease—Docetaxel—head and neck cancer	0.00165	0.00758	CcSEcCtD
Temsirolimus—Face oedema—Hydroxyurea—head and neck cancer	0.00158	0.00723	CcSEcCtD
Temsirolimus—Blood creatinine increased—Hydroxyurea—head and neck cancer	0.00153	0.00702	CcSEcCtD
Temsirolimus—Pleural effusion—Docetaxel—head and neck cancer	0.00153	0.007	CcSEcCtD
Temsirolimus—Rash maculo-papular—Fluorouracil—head and neck cancer	0.00147	0.00675	CcSEcCtD
Temsirolimus—Ageusia—Docetaxel—head and neck cancer	0.00144	0.00662	CcSEcCtD
Temsirolimus—Sepsis—Fluorouracil—head and neck cancer	0.00141	0.00645	CcSEcCtD
Temsirolimus—Depression—Vinblastine—head and neck cancer	0.00138	0.00631	CcSEcCtD
Temsirolimus—Thrombophlebitis—Fluorouracil—head and neck cancer	0.00136	0.00623	CcSEcCtD
Temsirolimus—Extravasation—Docetaxel—head and neck cancer	0.00134	0.00615	CcSEcCtD
Temsirolimus—Swelling—Fluorouracil—head and neck cancer	0.00133	0.00611	CcSEcCtD
Temsirolimus—Dysuria—Hydroxyurea—head and neck cancer	0.00132	0.00605	CcSEcCtD
Temsirolimus—Neutropenia—Hydroxyurea—head and neck cancer	0.00132	0.00605	CcSEcCtD
Temsirolimus—Infestation NOS—Hydroxyurea—head and neck cancer	0.00126	0.00577	CcSEcCtD
Temsirolimus—Infestation—Hydroxyurea—head and neck cancer	0.00126	0.00577	CcSEcCtD
Temsirolimus—Blood bilirubin increased—Docetaxel—head and neck cancer	0.00124	0.00567	CcSEcCtD
Temsirolimus—Dermatitis bullous—Fluorouracil—head and neck cancer	0.00123	0.00564	CcSEcCtD
Temsirolimus—Pharyngitis—Vinblastine—head and neck cancer	0.00123	0.00564	CcSEcCtD
Temsirolimus—Stomatitis—Hydroxyurea—head and neck cancer	0.00123	0.00563	CcSEcCtD
Temsirolimus—Gastrointestinal haemorrhage—Fluorouracil—head and neck cancer	0.00118	0.00539	CcSEcCtD
Temsirolimus—Phosphatase alkaline increased—Docetaxel—head and neck cancer	0.00117	0.00536	CcSEcCtD
Temsirolimus—Pulmonary embolism—Docetaxel—head and neck cancer	0.00117	0.00536	CcSEcCtD
Temsirolimus—Candida infection—Docetaxel—head and neck cancer	0.00112	0.00512	CcSEcCtD
Temsirolimus—Fluid retention—Docetaxel—head and neck cancer	0.00111	0.00509	CcSEcCtD
Temsirolimus—Dry skin—Fluorouracil—head and neck cancer	0.00108	0.00494	CcSEcCtD
Temsirolimus—Angiopathy—Hydroxyurea—head and neck cancer	0.00103	0.0047	CcSEcCtD
Temsirolimus—Dysphagia—Fluorouracil—head and neck cancer	0.00102	0.00466	CcSEcCtD
Temsirolimus—Sepsis—Docetaxel—head and neck cancer	0.00102	0.00465	CcSEcCtD
Temsirolimus—Chills—Hydroxyurea—head and neck cancer	0.00102	0.00465	CcSEcCtD
Temsirolimus—Anaemia—Vinblastine—head and neck cancer	0.000998	0.00457	CcSEcCtD
Temsirolimus—Erythema—Hydroxyurea—head and neck cancer	0.000985	0.00451	CcSEcCtD
Temsirolimus—Thrombophlebitis—Docetaxel—head and neck cancer	0.000981	0.0045	CcSEcCtD
Temsirolimus—Blood alkaline phosphatase increased—Docetaxel—head and neck cancer	0.000977	0.00447	CcSEcCtD
Temsirolimus—Leukopenia—Vinblastine—head and neck cancer	0.000967	0.00443	CcSEcCtD
Temsirolimus—Swelling—Docetaxel—head and neck cancer	0.000963	0.00441	CcSEcCtD
Temsirolimus—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.000945	0.00433	CcSEcCtD
Temsirolimus—Convulsion—Vinblastine—head and neck cancer	0.000936	0.00429	CcSEcCtD
Temsirolimus—Hypertension—Vinblastine—head and neck cancer	0.000932	0.00427	CcSEcCtD
Temsirolimus—Pneumonia—Fluorouracil—head and neck cancer	0.000912	0.00418	CcSEcCtD
Temsirolimus—Anaemia—Hydroxyurea—head and neck cancer	0.00091	0.00417	CcSEcCtD
Temsirolimus—Infestation NOS—Fluorouracil—head and neck cancer	0.000907	0.00416	CcSEcCtD
Temsirolimus—Infestation—Fluorouracil—head and neck cancer	0.000907	0.00416	CcSEcCtD
Temsirolimus—Dermatitis bullous—Docetaxel—head and neck cancer	0.000889	0.00407	CcSEcCtD
Temsirolimus—Stomatitis—Fluorouracil—head and neck cancer	0.000884	0.00405	CcSEcCtD
Temsirolimus—Conjunctivitis—Fluorouracil—head and neck cancer	0.000882	0.00404	CcSEcCtD
Temsirolimus—Urinary tract infection—Fluorouracil—head and neck cancer	0.000882	0.00404	CcSEcCtD
Temsirolimus—Leukopenia—Hydroxyurea—head and neck cancer	0.000881	0.00404	CcSEcCtD
Temsirolimus—Thrombocytopenia—Vinblastine—head and neck cancer	0.000863	0.00395	CcSEcCtD
Temsirolimus—Epistaxis—Fluorouracil—head and neck cancer	0.000856	0.00392	CcSEcCtD
Temsirolimus—Convulsion—Hydroxyurea—head and neck cancer	0.000853	0.00391	CcSEcCtD
Temsirolimus—Sinusitis—Fluorouracil—head and neck cancer	0.000851	0.0039	CcSEcCtD
Temsirolimus—Gastrointestinal haemorrhage—Docetaxel—head and neck cancer	0.00085	0.00389	CcSEcCtD
Temsirolimus—Anorexia—Vinblastine—head and neck cancer	0.00084	0.00385	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.000833	0.00381	CcSEcCtD
Temsirolimus—Rhinitis—Fluorouracil—head and neck cancer	0.000816	0.00374	CcSEcCtD
Temsirolimus—Pharyngitis—Fluorouracil—head and neck cancer	0.000808	0.0037	CcSEcCtD
Temsirolimus—Oedema—Hydroxyurea—head and neck cancer	0.000804	0.00368	CcSEcCtD
Temsirolimus—Infection—Hydroxyurea—head and neck cancer	0.000798	0.00366	CcSEcCtD
Temsirolimus—Dehydration—Docetaxel—head and neck cancer	0.00079	0.00362	CcSEcCtD
Temsirolimus—Nervous system disorder—Hydroxyurea—head and neck cancer	0.000788	0.00361	CcSEcCtD
Temsirolimus—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.000787	0.00361	CcSEcCtD
Temsirolimus—Skin disorder—Hydroxyurea—head and neck cancer	0.000781	0.00358	CcSEcCtD
Temsirolimus—Dry skin—Docetaxel—head and neck cancer	0.000779	0.00357	CcSEcCtD
Temsirolimus—Anorexia—Hydroxyurea—head and neck cancer	0.000766	0.00351	CcSEcCtD
Temsirolimus—Decreased appetite—Vinblastine—head and neck cancer	0.000766	0.00351	CcSEcCtD
Temsirolimus—Aspartate aminotransferase increased—Docetaxel—head and neck cancer	0.000765	0.0035	CcSEcCtD
Temsirolimus—Pain—Vinblastine—head and neck cancer	0.000754	0.00345	CcSEcCtD
Temsirolimus—Constipation—Vinblastine—head and neck cancer	0.000754	0.00345	CcSEcCtD
Temsirolimus—Alanine aminotransferase increased—Docetaxel—head and neck cancer	0.000749	0.00343	CcSEcCtD
Temsirolimus—Dysphagia—Docetaxel—head and neck cancer	0.000734	0.00336	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Vinblastine—head and neck cancer	0.000721	0.0033	CcSEcCtD
Temsirolimus—Dyspnoea—Hydroxyurea—head and neck cancer	0.000717	0.00328	CcSEcCtD
Temsirolimus—Somnolence—Hydroxyurea—head and neck cancer	0.000714	0.00327	CcSEcCtD
Temsirolimus—Erythema—Fluorouracil—head and neck cancer	0.000709	0.00325	CcSEcCtD
Temsirolimus—Decreased appetite—Hydroxyurea—head and neck cancer	0.000699	0.0032	CcSEcCtD
Temsirolimus—Abdominal pain—Vinblastine—head and neck cancer	0.000697	0.00319	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.000694	0.00318	CcSEcCtD
Temsirolimus—Fatigue—Hydroxyurea—head and neck cancer	0.000693	0.00317	CcSEcCtD
Temsirolimus—Pain—Hydroxyurea—head and neck cancer	0.000687	0.00315	CcSEcCtD
Temsirolimus—Constipation—Hydroxyurea—head and neck cancer	0.000687	0.00315	CcSEcCtD
Temsirolimus—Neutropenia—Docetaxel—head and neck cancer	0.000687	0.00315	CcSEcCtD
Temsirolimus—Weight decreased—Docetaxel—head and neck cancer	0.000664	0.00304	CcSEcCtD
Temsirolimus—Pneumonia—Docetaxel—head and neck cancer	0.000658	0.00302	CcSEcCtD
Temsirolimus—Anaemia—Fluorouracil—head and neck cancer	0.000655	0.003	CcSEcCtD
Temsirolimus—Infestation NOS—Docetaxel—head and neck cancer	0.000655	0.003	CcSEcCtD
Temsirolimus—Infestation—Docetaxel—head and neck cancer	0.000655	0.003	CcSEcCtD
Temsirolimus—Hypersensitivity—Vinblastine—head and neck cancer	0.000649	0.00297	CcSEcCtD
Temsirolimus—Stevens-Johnson syndrome—Docetaxel—head and neck cancer	0.000649	0.00297	CcSEcCtD
Temsirolimus—Renal failure—Docetaxel—head and neck cancer	0.000644	0.00295	CcSEcCtD
Temsirolimus—Stomatitis—Docetaxel—head and neck cancer	0.000638	0.00292	CcSEcCtD
Temsirolimus—Conjunctivitis—Docetaxel—head and neck cancer	0.000636	0.00292	CcSEcCtD
Temsirolimus—Body temperature increased—Hydroxyurea—head and neck cancer	0.000635	0.00291	CcSEcCtD
Temsirolimus—Leukopenia—Fluorouracil—head and neck cancer	0.000634	0.00291	CcSEcCtD
Temsirolimus—Asthenia—Vinblastine—head and neck cancer	0.000632	0.0029	CcSEcCtD
Temsirolimus—Epistaxis—Docetaxel—head and neck cancer	0.000617	0.00283	CcSEcCtD
Temsirolimus—Convulsion—Fluorouracil—head and neck cancer	0.000614	0.00281	CcSEcCtD
Temsirolimus—Myalgia—Fluorouracil—head and neck cancer	0.000603	0.00276	CcSEcCtD
Temsirolimus—Chest pain—Fluorouracil—head and neck cancer	0.000603	0.00276	CcSEcCtD
Temsirolimus—Diarrhoea—Vinblastine—head and neck cancer	0.000603	0.00276	CcSEcCtD
Temsirolimus—Hypersensitivity—Hydroxyurea—head and neck cancer	0.000592	0.00271	CcSEcCtD
Temsirolimus—Rhinitis—Docetaxel—head and neck cancer	0.000589	0.0027	CcSEcCtD
Temsirolimus—Pharyngitis—Docetaxel—head and neck cancer	0.000583	0.00267	CcSEcCtD
Temsirolimus—Dizziness—Vinblastine—head and neck cancer	0.000583	0.00267	CcSEcCtD
Temsirolimus—Urinary tract disorder—Docetaxel—head and neck cancer	0.00058	0.00266	CcSEcCtD
Temsirolimus—Oedema peripheral—Docetaxel—head and neck cancer	0.000579	0.00265	CcSEcCtD
Temsirolimus—Anaphylactic shock—Fluorouracil—head and neck cancer	0.000578	0.00265	CcSEcCtD
Temsirolimus—Oedema—Fluorouracil—head and neck cancer	0.000578	0.00265	CcSEcCtD
Temsirolimus—Connective tissue disorder—Docetaxel—head and neck cancer	0.000578	0.00265	CcSEcCtD
Temsirolimus—Asthenia—Hydroxyurea—head and neck cancer	0.000577	0.00264	CcSEcCtD
Temsirolimus—Urethral disorder—Docetaxel—head and neck cancer	0.000576	0.00264	CcSEcCtD
Temsirolimus—Infection—Fluorouracil—head and neck cancer	0.000575	0.00263	CcSEcCtD
Temsirolimus—Nervous system disorder—Fluorouracil—head and neck cancer	0.000567	0.0026	CcSEcCtD
Temsirolimus—Thrombocytopenia—Fluorouracil—head and neck cancer	0.000566	0.00259	CcSEcCtD
Temsirolimus—Vomiting—Vinblastine—head and neck cancer	0.00056	0.00257	CcSEcCtD
Temsirolimus—Erythema multiforme—Docetaxel—head and neck cancer	0.000556	0.00255	CcSEcCtD
Temsirolimus—Headache—Vinblastine—head and neck cancer	0.000552	0.00253	CcSEcCtD
Temsirolimus—Anorexia—Fluorouracil—head and neck cancer	0.000551	0.00253	CcSEcCtD
Temsirolimus—Diarrhoea—Hydroxyurea—head and neck cancer	0.00055	0.00252	CcSEcCtD
Temsirolimus—Eye disorder—Docetaxel—head and neck cancer	0.000549	0.00252	CcSEcCtD
Temsirolimus—Cardiac disorder—Docetaxel—head and neck cancer	0.000545	0.0025	CcSEcCtD
Temsirolimus—Angiopathy—Docetaxel—head and neck cancer	0.000533	0.00244	CcSEcCtD
Temsirolimus—Dizziness—Hydroxyurea—head and neck cancer	0.000531	0.00243	CcSEcCtD
Temsirolimus—Immune system disorder—Docetaxel—head and neck cancer	0.000531	0.00243	CcSEcCtD
Temsirolimus—Mediastinal disorder—Docetaxel—head and neck cancer	0.00053	0.00243	CcSEcCtD
Temsirolimus—Chills—Docetaxel—head and neck cancer	0.000527	0.00242	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.000527	0.00241	CcSEcCtD
Temsirolimus—Nausea—Vinblastine—head and neck cancer	0.000523	0.0024	CcSEcCtD
Temsirolimus—Insomnia—Fluorouracil—head and neck cancer	0.000523	0.0024	CcSEcCtD
Temsirolimus—Dyspnoea—Fluorouracil—head and neck cancer	0.000516	0.00236	CcSEcCtD
Temsirolimus—Mental disorder—Docetaxel—head and neck cancer	0.000515	0.00236	CcSEcCtD
Temsirolimus—Somnolence—Fluorouracil—head and neck cancer	0.000514	0.00236	CcSEcCtD
Temsirolimus—Erythema—Docetaxel—head and neck cancer	0.000512	0.00234	CcSEcCtD
Temsirolimus—Malnutrition—Docetaxel—head and neck cancer	0.000512	0.00234	CcSEcCtD
Temsirolimus—Vomiting—Hydroxyurea—head and neck cancer	0.000511	0.00234	CcSEcCtD
Temsirolimus—Rash—Hydroxyurea—head and neck cancer	0.000507	0.00232	CcSEcCtD
Temsirolimus—Dermatitis—Hydroxyurea—head and neck cancer	0.000506	0.00232	CcSEcCtD
Temsirolimus—Headache—Hydroxyurea—head and neck cancer	0.000503	0.00231	CcSEcCtD
Temsirolimus—Decreased appetite—Fluorouracil—head and neck cancer	0.000503	0.0023	CcSEcCtD
Temsirolimus—Dysgeusia—Docetaxel—head and neck cancer	0.000501	0.0023	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.000499	0.00229	CcSEcCtD
Temsirolimus—Back pain—Docetaxel—head and neck cancer	0.000495	0.00227	CcSEcCtD
Temsirolimus—Pain—Fluorouracil—head and neck cancer	0.000495	0.00227	CcSEcCtD
Temsirolimus—Nausea—Hydroxyurea—head and neck cancer	0.000477	0.00219	CcSEcCtD
Temsirolimus—Anaemia—Docetaxel—head and neck cancer	0.000473	0.00217	CcSEcCtD
Temsirolimus—Leukopenia—Docetaxel—head and neck cancer	0.000458	0.0021	CcSEcCtD
Temsirolimus—Body temperature increased—Fluorouracil—head and neck cancer	0.000457	0.0021	CcSEcCtD
Temsirolimus—Cough—Docetaxel—head and neck cancer	0.000446	0.00205	CcSEcCtD
Temsirolimus—Convulsion—Docetaxel—head and neck cancer	0.000443	0.00203	CcSEcCtD
Temsirolimus—Hypertension—Docetaxel—head and neck cancer	0.000442	0.00202	CcSEcCtD
Temsirolimus—Myalgia—Docetaxel—head and neck cancer	0.000436	0.002	CcSEcCtD
Temsirolimus—Arthralgia—Docetaxel—head and neck cancer	0.000436	0.002	CcSEcCtD
Temsirolimus—Chest pain—Docetaxel—head and neck cancer	0.000436	0.002	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.000433	0.00198	CcSEcCtD
Temsirolimus—Hypersensitivity—Fluorouracil—head and neck cancer	0.000426	0.00195	CcSEcCtD
Temsirolimus—Anaphylactic shock—Docetaxel—head and neck cancer	0.000418	0.00191	CcSEcCtD
Temsirolimus—Oedema—Docetaxel—head and neck cancer	0.000418	0.00191	CcSEcCtD
Temsirolimus—Infection—Docetaxel—head and neck cancer	0.000415	0.0019	CcSEcCtD
Temsirolimus—Nervous system disorder—Docetaxel—head and neck cancer	0.000409	0.00188	CcSEcCtD
Temsirolimus—Pruritus—Fluorouracil—head and neck cancer	0.000409	0.00188	CcSEcCtD
Temsirolimus—Thrombocytopenia—Docetaxel—head and neck cancer	0.000409	0.00187	CcSEcCtD
Temsirolimus—Skin disorder—Docetaxel—head and neck cancer	0.000406	0.00186	CcSEcCtD
Temsirolimus—Anorexia—Docetaxel—head and neck cancer	0.000398	0.00182	CcSEcCtD
Temsirolimus—Diarrhoea—Fluorouracil—head and neck cancer	0.000396	0.00181	CcSEcCtD
Temsirolimus—Dizziness—Fluorouracil—head and neck cancer	0.000383	0.00175	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.00038	0.00174	CcSEcCtD
Temsirolimus—Insomnia—Docetaxel—head and neck cancer	0.000378	0.00173	CcSEcCtD
Temsirolimus—Dyspnoea—Docetaxel—head and neck cancer	0.000372	0.00171	CcSEcCtD
Temsirolimus—Somnolence—Docetaxel—head and neck cancer	0.000371	0.0017	CcSEcCtD
Temsirolimus—Vomiting—Fluorouracil—head and neck cancer	0.000368	0.00169	CcSEcCtD
Temsirolimus—Rash—Fluorouracil—head and neck cancer	0.000365	0.00167	CcSEcCtD
Temsirolimus—Dermatitis—Fluorouracil—head and neck cancer	0.000364	0.00167	CcSEcCtD
Temsirolimus—Decreased appetite—Docetaxel—head and neck cancer	0.000363	0.00166	CcSEcCtD
Temsirolimus—Headache—Fluorouracil—head and neck cancer	0.000362	0.00166	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.00036	0.00165	CcSEcCtD
Temsirolimus—Fatigue—Docetaxel—head and neck cancer	0.00036	0.00165	CcSEcCtD
Temsirolimus—Pain—Docetaxel—head and neck cancer	0.000357	0.00164	CcSEcCtD
Temsirolimus—Constipation—Docetaxel—head and neck cancer	0.000357	0.00164	CcSEcCtD
Temsirolimus—Nausea—Fluorouracil—head and neck cancer	0.000344	0.00157	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Docetaxel—head and neck cancer	0.000341	0.00156	CcSEcCtD
Temsirolimus—Body temperature increased—Docetaxel—head and neck cancer	0.00033	0.00151	CcSEcCtD
Temsirolimus—Abdominal pain—Docetaxel—head and neck cancer	0.00033	0.00151	CcSEcCtD
Temsirolimus—Hypersensitivity—Docetaxel—head and neck cancer	0.000308	0.00141	CcSEcCtD
Temsirolimus—Asthenia—Docetaxel—head and neck cancer	0.0003	0.00137	CcSEcCtD
Temsirolimus—Pruritus—Docetaxel—head and neck cancer	0.000295	0.00135	CcSEcCtD
Temsirolimus—Diarrhoea—Docetaxel—head and neck cancer	0.000286	0.00131	CcSEcCtD
Temsirolimus—Dizziness—Docetaxel—head and neck cancer	0.000276	0.00126	CcSEcCtD
Temsirolimus—Vomiting—Docetaxel—head and neck cancer	0.000265	0.00122	CcSEcCtD
Temsirolimus—Rash—Docetaxel—head and neck cancer	0.000263	0.00121	CcSEcCtD
Temsirolimus—Dermatitis—Docetaxel—head and neck cancer	0.000263	0.00121	CcSEcCtD
Temsirolimus—Headache—Docetaxel—head and neck cancer	0.000262	0.0012	CcSEcCtD
Temsirolimus—Nausea—Docetaxel—head and neck cancer	0.000248	0.00114	CcSEcCtD
Temsirolimus—CYP2D6—Biological oxidations—GSTM1—head and neck cancer	0.000151	0.000885	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—MAPK3—head and neck cancer	0.00015	0.000879	CbGpPWpGaD
Temsirolimus—ABCB1—Transmembrane transport of small molecules—ATP7B—head and neck cancer	0.00015	0.000878	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—MAPK3—head and neck cancer	0.000149	0.000875	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—head and neck cancer	0.000149	0.000873	CbGpPWpGaD
Temsirolimus—CYP2D6—Metapathway biotransformation—GSTM1—head and neck cancer	0.000149	0.000872	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by VEGF—AKT1—head and neck cancer	0.000145	0.000853	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—MAPK1—head and neck cancer	0.000145	0.000852	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—MAPK1—head and neck cancer	0.000145	0.000852	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—MAPK1—head and neck cancer	0.000145	0.000852	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—EGFR—head and neck cancer	0.000145	0.000852	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—EGFR—head and neck cancer	0.000145	0.000852	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—EGFR—head and neck cancer	0.000145	0.000852	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—PIK3CA—head and neck cancer	0.000145	0.000848	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR—MAPK1—head and neck cancer	0.000144	0.000844	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR—EGFR—head and neck cancer	0.000144	0.000844	CbGpPWpGaD
Temsirolimus—CYP2D6—Biological oxidations—CYP1A1—head and neck cancer	0.000143	0.000839	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—MAPK1—head and neck cancer	0.000143	0.000837	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—EGFR—head and neck cancer	0.000143	0.000836	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB4—PIK3CA—head and neck cancer	0.000142	0.000835	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—MAPK1—head and neck cancer	0.000142	0.000833	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—EGFR—head and neck cancer	0.000142	0.000833	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—STAT3—head and neck cancer	0.000141	0.00083	CbGpPWpGaD
Temsirolimus—CYP2D6—Metapathway biotransformation—CYP1A1—head and neck cancer	0.000141	0.000827	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by SCF-KIT—HRAS—head and neck cancer	0.00014	0.00082	CbGpPWpGaD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—TP53—head and neck cancer	0.000138	0.000812	CbGpPWpGaD
Temsirolimus—MTOR—BDNF signaling pathway—HRAS—head and neck cancer	0.000138	0.000807	CbGpPWpGaD
Temsirolimus—MTOR—Insulin Signaling—PIK3CA—head and neck cancer	0.000137	0.000801	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signal transduction—PIK3CA—head and neck cancer	0.000136	0.000797	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—PIK3CA—head and neck cancer	0.000135	0.000793	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—MAPK3—head and neck cancer	0.000135	0.000793	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB2—PIK3CA—head and neck cancer	0.000135	0.000789	CbGpPWpGaD
Temsirolimus—MTOR—B Cell Activation—EGFR—head and neck cancer	0.000134	0.000788	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 signaling—PIK3CA—head and neck cancer	0.000134	0.000786	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—HRAS—head and neck cancer	0.000134	0.000785	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—UROD—head and neck cancer	0.000133	0.000783	CbGpPWpGaD
Temsirolimus—ABCB1—Allograft Rejection—VEGFA—head and neck cancer	0.000132	0.000777	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—PIK3CA—head and neck cancer	0.000132	0.000774	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB4—HRAS—head and neck cancer	0.000132	0.000772	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—MAPK1—head and neck cancer	0.000129	0.000754	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—EGFR—head and neck cancer	0.000129	0.000754	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—KISS1—head and neck cancer	0.000127	0.000742	CbGpPWpGaD
Temsirolimus—MTOR—Insulin Signaling—HRAS—head and neck cancer	0.000126	0.000741	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—PIK3CA—head and neck cancer	0.000126	0.000739	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—PIK3CA—head and neck cancer	0.000126	0.000739	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—PIK3CA—head and neck cancer	0.000126	0.000739	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signal transduction—HRAS—head and neck cancer	0.000126	0.000738	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—UROD—head and neck cancer	0.000126	0.000738	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—HRAS—head and neck cancer	0.000125	0.000734	CbGpPWpGaD
Temsirolimus—MTOR—EGF/EGFR Signaling Pathway—HRAS—head and neck cancer	0.000125	0.000734	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR—PIK3CA—head and neck cancer	0.000125	0.000732	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB2—HRAS—head and neck cancer	0.000125	0.00073	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 signaling—HRAS—head and neck cancer	0.000124	0.000727	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—PIK3CA—head and neck cancer	0.000124	0.000726	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by SCF-KIT—AKT1—head and neck cancer	0.000123	0.000724	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—PIK3CA—head and neck cancer	0.000123	0.000723	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—head and neck cancer	0.000122	0.000716	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—PTEN—head and neck cancer	0.000122	0.000714	CbGpPWpGaD
Temsirolimus—MTOR—BDNF signaling pathway—AKT1—head and neck cancer	0.000121	0.000712	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—BCL2L1—head and neck cancer	0.000119	0.0007	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—AKT1—head and neck cancer	0.000118	0.000693	CbGpPWpGaD
Temsirolimus—MTOR—Cellular responses to stress—VEGFA—head and neck cancer	0.000117	0.000687	CbGpPWpGaD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—AKT1—head and neck cancer	0.000117	0.000686	CbGpPWpGaD
Temsirolimus—MTOR—B Cell Activation—PIK3CA—head and neck cancer	0.000117	0.000684	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—HRAS—head and neck cancer	0.000117	0.000684	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—head and neck cancer	0.000117	0.000684	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—HRAS—head and neck cancer	0.000117	0.000684	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB4—AKT1—head and neck cancer	0.000116	0.000682	CbGpPWpGaD
Temsirolimus—MTOR—Cellular responses to stress—STAT3—head and neck cancer	0.000116	0.00068	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR—HRAS—head and neck cancer	0.000116	0.000678	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—HRAS—head and neck cancer	0.000115	0.000672	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—HRAS—head and neck cancer	0.000114	0.000669	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—PIK3CA—head and neck cancer	0.000112	0.000655	CbGpPWpGaD
Temsirolimus—MTOR—Insulin Signaling—AKT1—head and neck cancer	0.000112	0.000655	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signal transduction—AKT1—head and neck cancer	0.000111	0.000651	CbGpPWpGaD
Temsirolimus—MTOR—Cellular responses to stress—MAPK3—head and neck cancer	0.000111	0.00065	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—AKT1—head and neck cancer	0.000111	0.000648	CbGpPWpGaD
Temsirolimus—MTOR—EGF/EGFR Signaling Pathway—AKT1—head and neck cancer	0.000111	0.000648	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB2—AKT1—head and neck cancer	0.00011	0.000645	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 signaling—AKT1—head and neck cancer	0.000109	0.000642	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—STAT3—head and neck cancer	0.000109	0.000638	CbGpPWpGaD
Temsirolimus—MTOR—B Cell Activation—HRAS—head and neck cancer	0.000108	0.000633	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—AKT1—head and neck cancer	0.000108	0.000633	CbGpPWpGaD
Temsirolimus—MTOR—Cellular responses to stress—MAPK1—head and neck cancer	0.000105	0.000619	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—GRP—head and neck cancer	0.000104	0.000611	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—MAPK3—head and neck cancer	0.000104	0.00061	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—head and neck cancer	0.000103	0.000606	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—AKT1—head and neck cancer	0.000103	0.000604	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—AKT1—head and neck cancer	0.000103	0.000604	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—AKT1—head and neck cancer	0.000103	0.000604	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—NOTCH1—head and neck cancer	0.000102	0.000601	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR—AKT1—head and neck cancer	0.000102	0.000598	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—head and neck cancer	0.000102	0.000597	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—NAT2—head and neck cancer	0.000102	0.000596	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—STAT6—head and neck cancer	0.000101	0.000594	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—AKT1—head and neck cancer	0.000101	0.000593	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—AKT1—head and neck cancer	0.000101	0.00059	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—MAPK1—head and neck cancer	9.89e-05	0.00058	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—EGFR—head and neck cancer	9.89e-05	0.00058	CbGpPWpGaD
Temsirolimus—CYP3A4—Biological oxidations—GSTM1—head and neck cancer	9.86e-05	0.000578	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—CASP8—head and neck cancer	9.76e-05	0.000573	CbGpPWpGaD
Temsirolimus—ABCB1—HIF-1-alpha transcription factor network—AKT1—head and neck cancer	9.76e-05	0.000572	CbGpPWpGaD
Temsirolimus—CYP3A4—Metapathway biotransformation—GSTM1—head and neck cancer	9.73e-05	0.00057	CbGpPWpGaD
Temsirolimus—MTOR—B Cell Activation—AKT1—head and neck cancer	9.53e-05	0.000559	CbGpPWpGaD
Temsirolimus—CYP3A4—Biological oxidations—CYP1A1—head and neck cancer	9.35e-05	0.000548	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—CDH1—head and neck cancer	9.26e-05	0.000543	CbGpPWpGaD
Temsirolimus—CYP3A4—Metapathway biotransformation—CYP1A1—head and neck cancer	9.22e-05	0.000541	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—AKT1—head and neck cancer	9.12e-05	0.000535	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—YAP1—head and neck cancer	8.96e-05	0.000525	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—DPYD—head and neck cancer	8.91e-05	0.000522	CbGpPWpGaD
Temsirolimus—MTOR—Cellular responses to stress—TP53—head and neck cancer	8.85e-05	0.000519	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—head and neck cancer	8.73e-05	0.000512	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—PIK3CA—head and neck cancer	8.58e-05	0.000503	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—YAP1—head and neck cancer	8.45e-05	0.000496	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—BCL2—head and neck cancer	8.38e-05	0.000491	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—head and neck cancer	8.3e-05	0.000487	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—UROD—head and neck cancer	8.22e-05	0.000482	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—HRAS—head and neck cancer	7.94e-05	0.000466	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—PTGS2—head and neck cancer	7.61e-05	0.000446	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—head and neck cancer	7.5e-05	0.00044	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—NAT2—head and neck cancer	7.34e-05	0.000431	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—head and neck cancer	7.24e-05	0.000424	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—NOTCH1—head and neck cancer	7.18e-05	0.000421	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—AKT1—head and neck cancer	7.01e-05	0.000411	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—BCL2L1—head and neck cancer	6.96e-05	0.000408	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—PTEN—head and neck cancer	6.94e-05	0.000407	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—PTEN—head and neck cancer	6.66e-05	0.000391	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—PTEN—head and neck cancer	6.64e-05	0.000389	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—head and neck cancer	6.54e-05	0.000383	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—DPYD—head and neck cancer	6.44e-05	0.000378	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—head and neck cancer	6.18e-05	0.000363	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—YAP1—head and neck cancer	6.11e-05	0.000358	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—STAT3—head and neck cancer	5.94e-05	0.000348	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—MAPK3—head and neck cancer	5.93e-05	0.000348	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—head and neck cancer	5.88e-05	0.000345	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—head and neck cancer	5.88e-05	0.000345	CbGpPWpGaD
Temsirolimus—MTOR—Disease—NOTCH1—head and neck cancer	5.76e-05	0.000338	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—CASP8—head and neck cancer	5.69e-05	0.000333	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—MAPK3—head and neck cancer	5.67e-05	0.000333	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—MAPK1—head and neck cancer	5.64e-05	0.000331	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—EGFR—head and neck cancer	5.64e-05	0.000331	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—CDH1—head and neck cancer	5.62e-05	0.00033	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—NAT2—head and neck cancer	5.54e-05	0.000325	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—EGFR—head and neck cancer	5.42e-05	0.000318	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—MAPK1—head and neck cancer	5.4e-05	0.000316	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—EGFR—head and neck cancer	5.39e-05	0.000316	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—NAT2—head and neck cancer	5.22e-05	0.000306	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—head and neck cancer	5.1e-05	0.000299	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—TYMS—head and neck cancer	5.08e-05	0.000298	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—GSTM1—head and neck cancer	5.02e-05	0.000294	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—IL2—head and neck cancer	4.94e-05	0.00029	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—head and neck cancer	4.94e-05	0.00029	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—PIK3CA—head and neck cancer	4.9e-05	0.000287	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—BCL2—head and neck cancer	4.88e-05	0.000286	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—DPYD—head and neck cancer	4.86e-05	0.000285	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—CCND1—head and neck cancer	4.81e-05	0.000282	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—GPX1—head and neck cancer	4.81e-05	0.000282	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—CYP1A1—head and neck cancer	4.76e-05	0.000279	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—PIK3CA—head and neck cancer	4.7e-05	0.000276	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—PIK3CA—head and neck cancer	4.68e-05	0.000275	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—PTEN—head and neck cancer	4.65e-05	0.000273	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—YAP1—head and neck cancer	4.61e-05	0.00027	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—DPYD—head and neck cancer	4.58e-05	0.000269	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—HRAS—head and neck cancer	4.53e-05	0.000266	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—HRAS—head and neck cancer	4.35e-05	0.000255	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—YAP1—head and neck cancer	4.35e-05	0.000255	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—HRAS—head and neck cancer	4.33e-05	0.000254	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—IL2—head and neck cancer	4.3e-05	0.000252	CbGpPWpGaD
Temsirolimus—MTOR—Disease—PTGS2—head and neck cancer	4.28e-05	0.000251	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—VEGFA—head and neck cancer	4.2e-05	0.000246	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—head and neck cancer	4.17e-05	0.000245	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—STAT3—head and neck cancer	4.16e-05	0.000244	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—PTEN—head and neck cancer	4.04e-05	0.000237	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—NOTCH1—head and neck cancer	4.04e-05	0.000237	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—AKT1—head and neck cancer	4e-05	0.000235	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—MAPK3—head and neck cancer	3.97e-05	0.000233	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—AKT1—head and neck cancer	3.84e-05	0.000225	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—AKT1—head and neck cancer	3.82e-05	0.000224	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—MAPK1—head and neck cancer	3.78e-05	0.000222	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—EGFR—head and neck cancer	3.78e-05	0.000222	CbGpPWpGaD
Temsirolimus—MTOR—Disease—PTEN—head and neck cancer	3.73e-05	0.000219	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—TYMS—head and neck cancer	3.67e-05	0.000215	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—GSTM1—head and neck cancer	3.63e-05	0.000213	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—STAT3—head and neck cancer	3.62e-05	0.000212	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—GPX1—head and neck cancer	3.47e-05	0.000204	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—MAPK3—head and neck cancer	3.45e-05	0.000203	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—CYP1A1—head and neck cancer	3.44e-05	0.000202	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—NAT2—head and neck cancer	3.41e-05	0.0002	CbGpPWpGaD
Temsirolimus—MTOR—Disease—STAT3—head and neck cancer	3.34e-05	0.000196	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—MAPK1—head and neck cancer	3.29e-05	0.000193	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—EGFR—head and neck cancer	3.29e-05	0.000193	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—PIK3CA—head and neck cancer	3.28e-05	0.000192	CbGpPWpGaD
Temsirolimus—MTOR—Disease—MAPK3—head and neck cancer	3.19e-05	0.000187	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—TP53—head and neck cancer	3.17e-05	0.000186	CbGpPWpGaD
Temsirolimus—MTOR—Disease—MAPK1—head and neck cancer	3.03e-05	0.000178	CbGpPWpGaD
Temsirolimus—MTOR—Disease—EGFR—head and neck cancer	3.03e-05	0.000178	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—HRAS—head and neck cancer	3.03e-05	0.000178	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—DPYD—head and neck cancer	2.99e-05	0.000176	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—PIK3CA—head and neck cancer	2.85e-05	0.000167	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—YAP1—head and neck cancer	2.84e-05	0.000167	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PTGS2—head and neck cancer	2.83e-05	0.000166	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—IL2—head and neck cancer	2.78e-05	0.000163	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—TYMS—head and neck cancer	2.77e-05	0.000162	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—GSTM1—head and neck cancer	2.74e-05	0.000161	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CCND1—head and neck cancer	2.71e-05	0.000159	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—AKT1—head and neck cancer	2.68e-05	0.000157	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—HRAS—head and neck cancer	2.64e-05	0.000155	CbGpPWpGaD
Temsirolimus—MTOR—Disease—PIK3CA—head and neck cancer	2.63e-05	0.000154	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—GPX1—head and neck cancer	2.62e-05	0.000154	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PTEN—head and neck cancer	2.61e-05	0.000153	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—TYMS—head and neck cancer	2.61e-05	0.000153	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—CYP1A1—head and neck cancer	2.59e-05	0.000152	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—GSTM1—head and neck cancer	2.58e-05	0.000151	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—GPX1—head and neck cancer	2.47e-05	0.000145	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PTEN—head and neck cancer	2.47e-05	0.000145	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—CYP1A1—head and neck cancer	2.45e-05	0.000143	CbGpPWpGaD
Temsirolimus—MTOR—Disease—HRAS—head and neck cancer	2.44e-05	0.000143	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—VEGFA—head and neck cancer	2.36e-05	0.000138	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—STAT3—head and neck cancer	2.34e-05	0.000137	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—AKT1—head and neck cancer	2.33e-05	0.000137	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—MAPK3—head and neck cancer	2.23e-05	0.000131	CbGpPWpGaD
Temsirolimus—MTOR—Disease—AKT1—head and neck cancer	2.15e-05	0.000126	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—MAPK1—head and neck cancer	2.12e-05	0.000125	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—EGFR—head and neck cancer	2.12e-05	0.000125	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PTGS2—head and neck cancer	2.04e-05	0.00012	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PIK3CA—head and neck cancer	1.84e-05	0.000108	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—TP53—head and neck cancer	1.78e-05	0.000105	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PTEN—head and neck cancer	1.78e-05	0.000105	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PIK3CA—head and neck cancer	1.74e-05	0.000102	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—TYMS—head and neck cancer	1.71e-05	0.0001	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—HRAS—head and neck cancer	1.71e-05	0.0001	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GSTM1—head and neck cancer	1.69e-05	9.89e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GPX1—head and neck cancer	1.61e-05	9.47e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CYP1A1—head and neck cancer	1.6e-05	9.38e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PTGS2—head and neck cancer	1.54e-05	9.05e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—AKT1—head and neck cancer	1.51e-05	8.83e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PTGS2—head and neck cancer	1.45e-05	8.53e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—AKT1—head and neck cancer	1.42e-05	8.34e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PTEN—head and neck cancer	1.35e-05	7.89e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PTEN—head and neck cancer	1.27e-05	7.44e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PIK3CA—head and neck cancer	1.26e-05	7.38e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—AKT1—head and neck cancer	1.03e-05	6.03e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PTGS2—head and neck cancer	9.51e-06	5.58e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PIK3CA—head and neck cancer	9.49e-06	5.57e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PIK3CA—head and neck cancer	8.95e-06	5.25e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PTEN—head and neck cancer	8.29e-06	4.86e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—AKT1—head and neck cancer	7.76e-06	4.55e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—AKT1—head and neck cancer	7.31e-06	4.29e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PIK3CA—head and neck cancer	5.85e-06	3.43e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—AKT1—head and neck cancer	4.78e-06	2.8e-05	CbGpPWpGaD
